Clopidogrel
Clopidogrel, sold as Plavix, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists it to lower the rate of heart attack and stroke for people with acute coronary syndrome (unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed medically), and for people with an established peripheral arterial disease, a recent heart attack or a recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.
Also called Plavix
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 32968. UNII 08I79HTP27 is the UNII of clopidogrel bisulfate, the salt the label names, and is a broad match. The label read is the Sanofi-Aventis U.S. LLC label for Plavix, application NDA020839, effective 2025-05-30 in openFDA. Other clopidogrel labels in openFDA, including generic products and repackagers, were not read. This page records label indications, the title of the boxed warning and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 109 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 109
- Phase 3 or 4
- 91
- Recruiting
- 11
- Regulatory decisions
- 0
| Phase | Recruiting | Not yet recruiting | Completed | Terminated | Unknown status | All statuses |
|---|---|---|---|---|---|---|
| Phase 2 | 2 | 0 | 9 | 0 | 1 | 12 |
| Phase 2/3 | 0 | 0 | 1 | 0 | 2 | 3 |
| Phase 3 | 3 | 0 | 19 | 1 | 6 | 29 |
| Phase 4 | 5 | 3 | 35 | 3 | 16 | 62 |
| No phase | 1 | 0 | 1 | 0 | 1 | 3 |
| All phases | 11 | 3 | 65 | 4 | 26 | 109 |
Conditions these trials study
- Coronary artery disease
- Stroke
- Acute coronary syndrome
- Ischemic stroke
- Heart attack (myocardial infarction)
- Arrhythmia (heart rhythm problems)
- Atrial fibrillation (AF)
- Peripheral artery disease
- ST-elevation heart attack (STEMI)
- Unstable angina
Sponsors with the most trials
About this drug
- Level
- Substance
- Mechanism
- The label says an active metabolite of clopidogrel binds irreversibly to the P2Y12 class of ADP receptors on platelets, which inhibits platelet activation and aggregation.
Classification codes
-
08I79HTP27
Claims and evidence
Context People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 3 inclusion criteria; exclusion criteria not stated
- Included
- Patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction)
- Patients with acute ST-elevation myocardial infarction who are to be managed medically
- Patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke
- Excluded
- None stated
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (6)
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome (ACS)
- How it applies
- Label passage quoted in the research quote table (LB-05).
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Acute Coronary Syndrome (ACS), STEMI sentence
- How it applies
- Label passage quoted in the research quote table (LB-06).
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease
- How it applies
- Label passage quoted in the research quote table (LB-07).
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (LB-08).
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20250530.
- Retrieved
- Source effective date
- 2025-05-30
- Source state
- Current
- Version fingerprint
5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
PLAVIX
No label from the application holder was found in the openFDA label dataset for application NDA020839. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists non-ST-segment elevation acute coronary syndrome as an indication: Acute coronary syndrome
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists acute ST-elevation myocardial infarction managed medically as an indication: ST-elevation heart attack (STEMI)
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists a history of recent myocardial infarction as an indication: Heart attack (myocardial infarction)
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists recent stroke as an indication: Stroke
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists established peripheral arterial disease as an indication: Peripheral artery disease
Applies to Recipient not specified People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease
The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 1
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 3 efficacy supplement approvals on record.
Registry trials 109
Record details
- Record id
cardio:clopidogrel- Content hash
8e607e6e86e22dce3dbc717d293d344c57781197029baf8482e1a487e5fd776d